120 related articles for article (PubMed ID: 16584068)
1. Average bioequivalence evaluation: general methods for pilot trials.
Pan G; Wang Y
J Biopharm Stat; 2006; 16(2):207-25. PubMed ID: 16584068
[TBL] [Abstract][Full Text] [Related]
2. Pilot trial for the assessment of relative bioavailability in generic drug product development: statistical power.
Wang Y; Zhou S
J Biopharm Stat; 1999 Mar; 9(1):179-87. PubMed ID: 10091917
[TBL] [Abstract][Full Text] [Related]
3. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian approach to pilot-pivotal trials for bioequivalence assessment.
Lv D; Grayling MJ; Zhang X; Zhao Q; Zheng H
BMC Med Res Methodol; 2023 Dec; 23(1):301. PubMed ID: 38114931
[TBL] [Abstract][Full Text] [Related]
5. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline.
Karalis V; Symillides M; Macheras P
Eur J Pharm Sci; 2011 Nov; 44(4):497-505. PubMed ID: 21945487
[TBL] [Abstract][Full Text] [Related]
6. Sample size and the probability of a successful trial.
Chuang-Stein C
Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
[TBL] [Abstract][Full Text] [Related]
7. Sample size calculation for the Power Model for dose proportionality studies.
Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
[TBL] [Abstract][Full Text] [Related]
8. Equivalence assessment for interchangeability based on two-sided tests.
Dong X; Tsong Y
J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
[TBL] [Abstract][Full Text] [Related]
9. Blinded sample size re-estimation in crossover bioequivalence trials.
Golkowski D; Friede T; Kieser M
Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
[TBL] [Abstract][Full Text] [Related]
10. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
11. A modified large sample approach in the assessment of population bioequivalence.
Quiroz J; Ting N; Wei GC; Burdick RK
J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
[TBL] [Abstract][Full Text] [Related]
12. Pilot and Repeat Trials as Development Tools Associated with Demonstration of Bioequivalence.
Fuglsang A
AAPS J; 2015 May; 17(3):678-83. PubMed ID: 25732246
[TBL] [Abstract][Full Text] [Related]
13. Using aspects of study design in sample size estimation.
Phillips A; Campbell M
J Biopharm Stat; 1997 May; 7(2):215-26. PubMed ID: 9136065
[TBL] [Abstract][Full Text] [Related]
14. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use].
Zapater P; Horga JF
Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the statistical power for multiple tests: a case study.
Yeo A; Qu Y
Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
[TBL] [Abstract][Full Text] [Related]
16. A SAS macro for sample size adjustment and randomization test for internal pilot study.
Wang S; Xia J; Yu L; Li C; Xu L
Comput Methods Programs Biomed; 2008 Apr; 90(1):66-88. PubMed ID: 18192069
[TBL] [Abstract][Full Text] [Related]
17. Blinded sample size recalculation in multicentre trials with normally distributed outcome.
Jensen K; Kieser M
Biom J; 2010 Jun; 52(3):377-99. PubMed ID: 20394080
[TBL] [Abstract][Full Text] [Related]
18. Average bioequivalence for two-sequence two-period crossover design with incomplete data.
Lee JY; Kim BC; Park SG
J Biopharm Stat; 2005; 15(5):857-67. PubMed ID: 16078389
[TBL] [Abstract][Full Text] [Related]
19. Acupuncture for chronic neck pain: a pilot for a randomised controlled trial.
Salter GC; Roman M; Bland MJ; MacPherson H
BMC Musculoskelet Disord; 2006 Dec; 7():99. PubMed ID: 17156464
[TBL] [Abstract][Full Text] [Related]
20. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
Nguyen TT; Bazzoli C; Mentré F
Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
